Bozeman, MT (October 1, 2008) – Golden Helix, Inc., the global leader in genetic association software, today announced that the US Centers for Disease Control and Prevention (CDC) has expanded its licensing agreement for the Golden Helix SNP and Variation Suite.
While the CDC has been a Golden Helix customer for several years, this marks an expansion into a third organization within the CDC – the Division of Blood Disorders (DBD) – and also includes the purchase of additional functionality. The products licensed include HelixTree for population-based association studies, PBAT for family-based studies, and CNAM, Golden Helix’s advanced copy number association tool.
The DBD will use the software for complex whole-genome association studies.
“Researchers at the CDC have both the need and the wherewithal to buy the best tools available for their important research. We’re pleased they continue to choose ours,” said Josh Forsythe, Director of Marketing for Golden Helix. “We continually invest in our products, with the single goal of ensuring they remain the most effective and powerful tools for genetic research.”
About Golden Helix
Founded in 1998, Golden Helix has become the global leader in SNP and copy number analysis, genetic association software, and services. Using advanced technologies, Golden Helix provides a comprehensive suite of software tools and services enabling its customers to understand the genetic causes of disease, transform drug discovery, create predictive diagnostics, and advance the pursuit of personalized medicine. The company's products are used by hundreds of researchers at the world's top pharmaceutical, biotech, and non-profit research organizations, and have been cited in over 100 peer reviewed publications that detail groundbreaking research uncovering the genetic and environmental basis of disease. Golden Helix is committed to Accelerating the Quest for Significance. For more information, please visit www.goldenhelix.com.
Director of Marketing
Golden Helix, Inc.